Researchers from Duke Clinical Research Institute evaluated the impact of vascular conduit storage solutions on VGF rates and clinical outcomes through a sub-analysis of data from the prospective ...

Humacyte Advances in Vascular Repair with Innovative Bioengineered Tissues. Humacyte (NASDAQ:HUMA) is developing universally implantable, bioengineered human tissues.Their lead product candidates ...

DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL, Oct. 06, 2023 (GLOBE ...

DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit solution indicated ...

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to ...

DuraGraft, which received De Novo FDA Clearance on October 4, 2023, is designated for use as a vascular conduit solution for adult patients undergoing Coronary Artery Bypass Grafting surgeries.

Somahlution today announced today that it has received European market (CE) approval for DuraGraft, the first-in-class Endothelial Damage Inhibitor (EDI) that uniquely protects vascular ...

DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries With the granting of this de novo ...

Marizyme, Inc. Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft 06-Oct-2023 / 15:00 CET/CEST ...